A carregar...

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

BACKGROUND: A growing number of treatment options exist to treat metastatic castrate-resistant prostate cancer (mCRPC), and with these newer options, many questions about optimising treatment remain unanswered. One recommendation that may potentially be overlooked by practitioners is that androgen d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Urol
Main Authors: Merseburger, Axel S., Hammerer, Peter, Rozet, Francois, Roumeguère, Thierry, Caffo, Orazio, da Silva, Fernando Calais, Alcaraz, Antonio
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512260/
https://ncbi.nlm.nih.gov/pubmed/25261259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-014-1406-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!